The company will initiate a clinical study of imlifidase in patients with DMD with pre-existing IgG Abs to Sarepta’s SRP-9001. The study is expected to be commenced in 2023
In the preclinical studies, the results showed the ability of imlifidase to reduce pre-existing IgG Abs to rAAVrh74 for safe & successful administer SRP-9001. Imlifidase is marketed under the trade name Idefirix & has conditional marketing approval in the EU for highly sensitized adult kidney transplant patients who have a positive crossmatch against an available deceased donor
In 2020, Sarepta got exclusive rights globally for imlifidase as a pre-treatment for DMD & LGMD where Hansa received ~$397.5M in development, regulatory & sales milestones along with royalties
Ref: PRNewswire | Image: Hansa
